Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

OBIO

Orchestra BioMed Holdings Inc

May 13 • 04:00PM ET

4.06

0.00 0.00 %

Healthcare • Biotechnology • USA • Micro • NASD

May 12, 6:15 PMOrchestra BioMed Holdings Inc reports fiscal Q1 2026 results with non-GAAP EPS $-0.33 (+33% YoY) and revenue $110,000 (-87% YoY), beats EPS but misses revenue estimates

Peers: CAPR TNYA ATRC AORT BCDA

| Held by: VTI VXF SURI SCHA IWC SCHB AVSC IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	31.16%	Shs Outstand	58.63M	Perf Week	-1.22%
Market Cap	237.59M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	0.08%	Shs Float	40.29M	Perf Month	-9.98%
Enterprise Value	186.59M	PEG	-	EPS next Q	-0.43	Inst Own	41.58%	Short Float	2.41%	Perf Quarter	0.00%
Income	-54.86M	P/S	7.26	EPS this Y	-52.33%	Inst Trans	4.08%	Short Ratio	4.87	Perf Half Y	7.41%
Sales	32.72M	P/B	5.78	EPS next Y	16.41%	ROA	-68.42%	Short Interest	0.97M	Perf YTD	-2.17%
Book/sh	0.70	P/C	2.52	EPS next 5Y	4.89%	ROE	-161.12%	52W High	5.42 -25.15%	Perf Year	38.10%
Cash/sh	1.61	P/FCF	-	EPS past 3/5Y	20.91% -164.92%	ROIC	-65.19%	52W Low	2.20 84.55%	Perf 3Y	-76.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	111.62% -	Gross Margin	98.65%	Volatility	6.63% 5.49%	Perf 5Y	-60.35%
Dividend TTM	-	EV/Sales	5.70	EPS Y/Y TTM	22.24%	Oper. Margin	-167.96%	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.01	Sales Y/Y TTM	1033.89%	Profit Margin	-167.63%	RSI (14)	47.49	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	7.03	EPS Q/Q	32.86%	SMA20	-1.00%	Beta	0.52	Target Price	12.57
Payout	-	Debt/Eq	0.66	Sales Q/Q	-87.33%	SMA50	-5.59%	Rel Volume	0.96	Prev Close	4.06
Employees	86	LT Debt/Eq	0.64	Earnings	May 12 AMC	SMA200	6.63%	Avg Volume	199.79K	Price	4.06
IPO	Aug 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.34% -88.03%	Trades		Volume	192,097	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Initiated	TD Cowen	Buy	$15
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy	$12
Jan-02-25	Initiated	Barclays	Overweight	$16
Aug-22-24	Initiated	H.C. Wainwright	Buy	$14
Jul-25-24	Initiated	B. Riley Securities	Buy	$15
Jan-19-24	Initiated	Jefferies	Buy	$14
Feb-24-23	Initiated	Piper Sandler	Overweight	$15
Feb-07-23	Initiated	Chardan Capital Markets	Buy	$20

May-12-26 04:18PM	Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:30AM	Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 (GlobeNewswire)
May-06-26 08:01AM	Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement (GlobeNewswire)
08:00AM	Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement (GlobeNewswire)
Apr-30-26 09:00AM	FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy (GlobeNewswire) +5.00%
12:00PM	Loading…
Apr-23-26 12:00PM	Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 (GlobeNewswire)
Mar-12-26 08:17AM	Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-03-26 08:00AM	Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT (GlobeNewswire)
Feb-19-26 08:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire)
Feb-13-26 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 09:00AM	Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics (GlobeNewswire)
Dec-31-25 11:13AM	TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs (Insider Monkey)
Dec-08-25 07:00AM	Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting (GlobeNewswire)
Nov-29-25 01:25AM	Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements (Insider Monkey)
Nov-26-25 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:00AM	Loading…
Nov-11-25 09:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) +8.47%
07:31AM	What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings (GuruFocus.com)
Nov-10-25 05:30PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:10PM	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.32%
Nov-03-25 08:00AM	Orchestra BioMed to Host Business Update Call on November 12, 2025 (GlobeNewswire)
Oct-28-25 08:00AM	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements (GlobeNewswire)
Oct-27-25 09:00AM	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial (GlobeNewswire)
Oct-09-25 08:00AM	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit (GlobeNewswire)
Sep-04-25 05:00PM	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout (GlobeNewswire)
Aug-26-25 07:30AM	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology (GlobeNewswire) +15.38%
Aug-14-25 08:00AM	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction (GlobeNewswire)
Aug-13-25 08:00AM	Campbellford Memorial Hospitals New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO® (Business Wire)
Aug-12-25 03:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +7.94%
08:14AM	Loading…
08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-08-25 07:00AM	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Aug-04-25 05:55PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.84%
Aug-01-25 07:59AM	Orchestra BioMed Announces Pricing of $40 Million Public Offering (GlobeNewswire) -20.26%
Jul-31-25 04:02PM	Orchestra BioMed Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-16-25 08:00AM	OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets (Business Wire) +7.88%
Jun-18-25 09:30AM	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 (GlobeNewswire) -11.01%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-12-25 05:40PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.94%
04:28PM	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones (GlobeNewswire)
May-07-25 08:30AM	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure (GlobeNewswire)
May-06-25 05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.47%
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.57%
Apr-29-25 09:00AM	Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon (GlobeNewswire)
Apr-28-25 04:30PM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) -6.12%
Apr-23-25 09:00AM	Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting (GlobeNewswire)
Apr-22-25 07:00AM	Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy (GlobeNewswire)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -24.30%
04:21PM	Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update (GlobeNewswire)
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-20-25 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -8.77%
Feb-18-25 08:00AM	Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board (GlobeNewswire)
Feb-12-25 10:43AM	Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference (GlobeNewswire)
Feb-05-25 08:00AM	Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors (GlobeNewswire)
Dec-09-24 07:00AM	Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting (GlobeNewswire) +9.54%
Nov-26-24 04:05PM	Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.67% +7.24%
04:12PM	Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-24 08:00AM	Orchestra BioMed to Participate in Jefferies London Healthcare Conference (GlobeNewswire) -5.50%
Aug-12-24 05:35PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-24 09:35AM	Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.55%
Aug-01-24 10:01AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -7.18%
Jul-30-24 08:00AM	Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors (GlobeNewswire)
Jul-26-24 12:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know (Zacks) -6.70%
09:55AM	Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade (Zacks)
Jul-23-24 09:00AM	Precision Neuroscience Expands Executive Team as Brain Computer Interface Industry Rapidly Advances (GlobeNewswire)
Jun-24-24 08:07AM	Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar? (Zacks) +9.02%
Jun-04-24 08:00AM	Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire) +10.64%
Jun-03-24 12:00PM	All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy (Zacks)
09:55AM	Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect? (Zacks)
May-22-24 08:43AM	Orchestra BioMed to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 09:53PM	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +13.04%
06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:58PM	Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-30-24 08:30AM	Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM	Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM	Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM	Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM	Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM	Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Nov-13-23 04:21PM	Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +14.61% +13.08%
Nov-09-23 04:42PM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
Sep-19-23 02:37PM	Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach (TheStreet.com) +27.61%
07:30AM	Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire) -7.74%
Aug-10-23 04:34PM	Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.05%
Aug-08-23 08:30AM	Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis (GlobeNewswire)
Jul-27-23 09:47AM	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28% (Simply Wall St.) -14.00%
Jun-28-23 02:16PM	Why Shares of Orchestra BioMed Holdings Jumped Wednesday (Motley Fool) +24.85%
Jun-26-23 08:00AM	Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes (GlobeNewswire) -9.81%
Jun-07-23 08:30AM	Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer (GlobeNewswire) -6.42%

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RTW INVESTMENTS, LP	10% Owner	Apr 27 '26	Sale	4.13	32	132	9,556,063	Apr 29 05:36 PM
Hochman David P	See Remarks	Mar 13 '26	Buy	4.29	10,000	42,900	1,086,467	Mar 16 04:54 PM
Hochman David P	See Remarks	Nov 14 '25	Buy	4.07	5,000	20,350	612,822	Nov 17 05:00 PM
Aryeh Jason	Director	Sep 19 '25	Buy	2.45	1,000	2,450	108,482	Sep 19 06:57 PM
Fain Eric S	Director	Aug 25 '25	Buy	2.61	5,760	15,034	71,709	Aug 25 07:04 PM
Sherman Darren	See Remarks	Aug 25 '25	Buy	2.62	3,000	7,860	926,837	Aug 25 07:04 PM
Hochman David P	See Remarks	Aug 21 '25	Buy	2.49	6,000	14,940	651,460	Aug 25 07:03 PM
Taylor Andrew Lawrence	Chief Financial Officer	Aug 25 '25	Buy	2.55	2,000	5,100	482,788	Aug 25 07:01 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 01 '25	Buy	2.75	700,000	1,925,000	5,292,556	Aug 05 10:46 AM
Hochman David P	See Remarks	Aug 04 '25	Buy	2.75	20,000	55,000	349,331	Aug 04 06:16 PM
Fain Eric S	Director	Jun 26 '25	Sale	3.05	2,683	8,183	50,949	Jun 27 05:10 PM
Fain Eric S	Director	Jun 26 '25	Proposed Sale	3.05	2,683	8,194		Jun 26 03:11 PM

Open in Screener

KLRA

Kailera Therapeutics Inc

May 13 • 04:00PM ET

21.11

-1.19 -5.34 %

Healthcare • Biotechnology • USA • Mid • NASD

KLRA Kailera Therapeutics Inc daily Stock Chart

Peers: NTLA TWST RXRX VERA BEAM

| Held by: OZEM TNXT

Index	-	P/E	-	EPS (ttm)	-	Insider Own	32.50%	Shs Outstand	129.54M	Perf Week	-14.53%
Market Cap	2.73B	Forward P/E	-	EPS next Y	-3.55	Insider Trans	94.20%	Shs Float	87.44M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	12.18%	Short Float	2.24%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-153.84%	Inst Trans	24.69%	Short Ratio	1.54	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-0.61%	ROA	-	Short Interest	1.95M	Perf YTD	-18.81%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	28.23 -25.21%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	20.86 1.17%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.11% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-11.70%	Beta	-	Target Price	42.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-11.70%	Rel Volume	0.28	Prev Close	22.30
Employees	145	LT Debt/Eq	-	Earnings	-	SMA200	-11.70%	Avg Volume	1.27M	Price	21.11
IPO	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	349,546	Change	-5.34%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	William Blair	Outperform
May-12-26	Initiated	TD Cowen	Buy	$57
May-12-26	Initiated	Leerink Partners	Outperform	$36
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	Jefferies	Buy	$48
May-12-26	Initiated	Evercore ISI	Outperform

Today 07:30AM	Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire) -5.34%
May-12-26 12:50PM	Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity (Investor's Business Daily)
Apr-20-26 04:05PM	Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.35%

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RTW INVESTMENTS, LP	10% Owner	Apr 20 '26	Buy	16.00	500,000	8,000,000	10,776,820	Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:10 PM
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:08 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:01 PM
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:00 PM

OBIO

Orchestra BioMed Holdings Inc

KLRA

Kailera Therapeutics Inc

Upgrade your Finviz experience